Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
J-Pharma Co. Ltd. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners, ensuring that each of the 2 pending office actions is evaluated independently. The portfolio is concentrated in 1 distinct art unit, suggesting that the pharmaceutical innovations being patented are technically related. This allows for a consistent legal strategy that addresses the specific requirements and precedents of that 1 distinct art unit.
YOUNGBLOOD, WILLIAM JUSTIN is the busiest examiner, overseeing 1 busiest examiner pending action. Given that there are 2 pending office actions and 2 distinct examiners, the workload is evenly divided. This distribution minimizes the impact of any single examiner's personal review style on the overall portfolio. However, the reliance on 1 distinct art unit means that the company must remain highly attuned to the specific examination culture of that single department. Practitioners should focus on the 1 distinct art unit's standards while responding to the 2 distinct examiners currently reviewing the applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.7% |
| GAUGER, PAUL RANDALL | 1 | 56.0% | +12.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638669 | A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER USED FOR A PATIENT HAVING SPECIFIC GENETIC MARKER | GAUGER, PAUL RANDALL | 4d overdue |
| 18771230 | METHOD OF TREATING BILIARY TRACT CANCER | YOUNGBLOOD, WILLIAM JUSTIN | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18771230 | METHOD OF TREATING BILIARY TRACT CANCER | YOUNGBLOOD, WILLIAM JUSTIN | — | §102§103§112DP | Non-Final OA | — | Pending | Jul 12, 2024 |
| 17638669 | A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER USED FOR A PATIENT HAVING SPECIFIC GENETIC MARKER | GAUGER, PAUL RANDALL | 1629 | — | Final Rejection | 4d overdue | Pending | Feb 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial